Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Prospective randomised trial of stented versus stentless bioprosthesis for aortic valve replacement (AVR)
ISRCTN ISRCTN56511757
ClinicalTrials.gov identifier
Public title Prospective randomised trial of stented versus stentless bioprosthesis for aortic valve replacement (AVR)
Scientific title
Acronym N/A
Serial number at source P00715
Study hypothesis To find out which prosthetic valves represent the better option for patients requiring AVR.
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Aortic valve replacement
Participants - inclusion criteria Inclusion criteria:
1. Patients who require elective AVR with a tissue valve for symptomatic aortic valve stenosis (peak valve gradient equal to or greater than 50 mmHg as measured by echocardiography), with or without concomitant artery bypass grafting
2. Patients = 65 years of age at the time of surgery
Participants - exclusion criteria 1. Patients who are already enrolled in another major cardiovascular trial
2. AVR performed primarily for aortic valve regurgitation
3. Active aortic valve infection
4. Active malignant disease
5. Renal failure requiring dialysis
6. Any previous cardiac surgery
7. The need for additional cardiac procedures other than coronary artery bypass grafting
8. Emergency operations
9. Patients unable to give informed consent
Anticipated start date 01/03/2001
Anticipated end date 05/07/2005
Status of trial Completed
Patient information material
Target number of participants 240
Interventions Prima Plus (Edwards Lifesciences) stentless bioprosthesis or the Carpentier-Edwards Perimount stented bioprosthesis (Edwards Lifesciences).
Primary outcome measure(s) Post-operative pressure gradient across the prosthetic valve and effective valve orifice area.
Secondary outcome measure(s) No secondary outcome measures
Sources of funding Edwards LifeSciences Ltd (UK) - Industrial grant
Trial website
Publications Results in http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17532416
Contact name Mr  Steven  Tsui
  Address Surgical Unit
Papworth Hospital NHS Trust
  City/town Papworth Everard
  Zip/Postcode CB3 8RE
  Country United Kingdom
Sponsor Papworth Hospital NHS Trust (UK)
  Address Surgical Unit
  City/town Papworth Everard
  Zip/Postcode CB3 8RE
  Country United Kingdom
Date applied 16/05/2005
Last edited 04/10/2007
Date ISRCTN assigned 08/07/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central